Equities research analysts expect that VIVUS, Inc. (NASDAQ:VVUS) will announce earnings per share of ($0.13) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for VIVUS’s earnings. VIVUS posted earnings per share of ($0.09) in the same quarter last year, which indicates a negative year over year growth rate of 44.4%. The business is scheduled to issue its next earnings results on Wednesday, November 8th.
On average, analysts expect that VIVUS will report full-year earnings of ($0.39) per share for the current fiscal year. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow VIVUS.
A number of brokerages have recently weighed in on VVUS. Zacks Investment Research upgraded VIVUS from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Monday, July 17th. ValuEngine lowered VIVUS from a “buy” rating to a “hold” rating in a research note on Friday.
VIVUS (NASDAQ VVUS) opened at 0.8988 on Friday. VIVUS has a 12 month low of $0.87 and a 12 month high of $1.47. The company has a market cap of $95.10 million, a price-to-earnings ratio of 2.8994 and a beta of 0.86. The company has a 50-day moving average of $1.06 and a 200-day moving average of $1.10.
ILLEGAL ACTIVITY NOTICE: “VIVUS, Inc. (VVUS) Expected to Announce Earnings of -$0.13 Per Share” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://ledgergazette.com/2017/09/17/vivus-inc-vvus-expected-to-announce-earnings-of-0-13-per-share.html.
Several hedge funds have recently made changes to their positions in VVUS. Spark Investment Management LLC acquired a new stake in shares of VIVUS during the second quarter worth $100,000. Nine Chapters Capital Management LLC acquired a new stake in shares of VIVUS during the first quarter worth $113,000. Bank of New York Mellon Corp raised its stake in shares of VIVUS by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 106,842 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 3,694 shares during the period. Russell Investments Group Ltd. raised its stake in shares of VIVUS by 84.8% in the second quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 68,200 shares during the period. Finally, Northern Trust Corp raised its stake in shares of VIVUS by 16.8% in the second quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 39,473 shares during the period. Institutional investors own 35.82% of the company’s stock.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.